Search

Displaying results 4421 - 4430 of 9322 in total
  1. Drug

    Lexacalcitol

    go.drugbank.com/drugs/DB03451
    Experimental

    It is known to target the vitamin D3 receptor. … This compound belongs to the vitamin D and derivatives class of chemicals. These are compounds containing a secosteroid backbone, usually secoergostane or secocholestane.

  2. Drug

    RG2417

    go.drugbank.com/drugs/DB05055
    Investigational

    This new insight suggests that the symptoms of bipolar disorder may be linked to dysregulation of energy metabolism of the brain. … Uridine is synthesized by the mitochondria, the power plant of the human cell responsible for energy metabolism.

  3. Drug

    RTP-801i

    go.drugbank.com/drugs/DB06048
    Investigational

    RTP-801i is an siRNA drug candidate designed to inhibit the expression of the hypoxia-inducible gene RTP801. … The proposed primary indication for RTP-801i is the treatment of patients with neovascular (wet) Age-related Macular Degeneration (AMD or ARMD).

  4. Drug

    NGX267

    go.drugbank.com/drugs/DB05152
    Investigational

    It is developed for the treatment of Alzheimer’s disease and has shown the potential to both reduce symptoms and slow disease progression.

  5. Drug

    scyllo-inositol

    go.drugbank.com/drugs/DB03106
    Investigational

    (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction. Scyllitol has been investigated for the treatment of Alzheimer Disease. … An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man.

  6. Drug

    XAV-19

    go.drugbank.com/drugs/DB15895
    Investigational

    The therapy offers three beneficial effects: the ability to neutralize the virus, reduce inflammatory responses, and the absence of aggravating reactions following treatment[L16563]. … Xenothera has partnered with LFB, a pharmaceutical company, to develop XAV-19, and with Nantes University Hospital to test the treatment in patients[L16553,L16558].

  7. Drug

    NKG2D-ACE2 CAR-NK Cell

    go.drugbank.com/drugs/DB15727
    Investigational

    The IL-15 superagonist increases the activity of NK cells and improves their target cytotoxicity. The GM-CSF acts as a neutralizer for the CAR-T cell-mediated cytokine release and neurotoxicity. … The ACE2 is a receptor for SARS-Cov-2, binding to the S-protein of the viral envelope and competitively inhibiting SARS-Cov-2 infection of type II alveolar epithelial cells.

  8. Drug

    Egaptivon pegol

    go.drugbank.com/drugs/DB05202
    Investigational

    [A3290, A259053] Egaptivon pegol is a therapeutic oligonucleotide ("aptamer") which blocks the binding of the A1 domain of vWF to the platelet GPIb receptor, thereby modulating platelet adhesion, activation … Egaptivon pegol, formerly known as ARC1779, is a therapeutic aptamer antagonist of the A1 domain of von Willebrand Factor (vWF), the ligand for receptor glycoprotein 1b on platelets.

  9. Drug

    LX201

    go.drugbank.com/drugs/DB04943
    Investigational

    LX201 is a silicone matrix ocular implant that provides sustained release of cyclosporine A (CsA) locally to the eye over the course of one year. … LX201 is implanted subconjunctivally (beneath the transparent membrane covering the white of the eye) in a minimally invasive procedure.

  10. Drug

    Erythroxylum catuaba bark

    go.drugbank.com/drugs/DB14300
    Investigational

    "Catuaba" is a general term for a medicinal infusion created by the bark of plants belonging to the _Erythroxylum_ genus, though this name is also applied to infusions of plants belonging to other genera … [A215262] The infusion is thought to carry stimulant and aphrodisiac effects,[A215262] and catuaba made specifically with _Trichilia catigua_ has been investigated for use in depression.[A215267]